Skip to main content

Infliximab (Remicade)

Infliximab is a treatment option for treating:

  • Rheumatoid arthritis
  • Psoriatic arthritis
  • Ulcerative colitis
  • Crohn's disease
  • Ankylosing spondylitis

- It is administered through intravenous infusion every 6-8 weeks.

- It is an anti-TNF immunosuppressive that binds and clears TNF

- European sales in 2016 were €1.5 billion

- It has an immunogenicity rate of 60%

Labs that test for drug level:
Karolinska University Lab
University of Tours
KU Leuven

Labs that test for ADA titre:
KU Leuven
Sheba Medical Centre

Labs that test for immune complexes:
Karolinska Institutet